Florida is currently home to 3831 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Recruiting
Patients will receive a vaccine called SurVaxM on this study. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer. SurVaxM is designed to tell the body's immune system to look for tumor cells that express a protein called survivin and destroy them. The survivin protein can be found on up to 95% of glioblastomas and other types of cancer but is not found in normal cells. If the body's immune system knows to destroy cells that express surviv... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
04/11/2025
Locations: University of Florida, Gainsville, Florida
Conditions: Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High-grade Astrocytoma NOS, Anaplastic Oligodendroglioma, Anaplastic Ependymoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Recruiting
The study purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: University of Miami Hospital and Clinics, Miami, Florida
Conditions: Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Recruiting
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida
Conditions: Metastatic Urothelial Cancer
Hairy Cell Leukemia Patient Data Registry
Recruiting
The overall objective is to develop a clinical data registry that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality and improving the quality of life of patients diagnosed or living with hairy cell leukemia. With approximately 1,000 new cases of this rare disease identified in the US each year, HCL represents 2% of all cases of leukemia in adults. Considering the rarity of this chronic leukemia, the Hairy Cell Leukemia Foundation (HCLF), in part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: University of Miami/Soffer Clinical Research Center, Miami, Florida
Conditions: Leukemia, Other
iTBS/fMRI Study of Apex Control
Recruiting
The objective of this study is to examine the effect of transcranial magnetic stimulation (TMS) on the prefrontal cortex and posterior parietal cortex.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
04/10/2025
Locations: Florida State University Psychology Department Building, Tallahassee, Florida
Conditions: Transcranial Magnetic Stimulation
Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study
Recruiting
Dual antiplatelet therapy (DAPT) with low-dose aspirin and a P2Y12 inhibitor is the current standard of care in patients with coronary artery disease experiencing an acute event or undergoing percutaneous coronary intervention. However, the ischemic benefits are counterbalanced by a significant increase in bleeding events. Over time, different DAPT de-escalation strategies have been developed to reduce the bleeding risk while maintaining the ischemic protection, but there is currently no head-to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: University of Florida, Jacksonville, Florida
Conditions: Coronary Artery Disease
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
Recruiting
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
Gender:
ALL
Ages:
Between 18 years and 83 years
Trial Updated:
04/10/2025
Locations: Jacksonville, Jacksonville, Florida
Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Effectiveness of Phenazopyridine for Pain Following Urodynamics
Recruiting
The purpose of the study is to determine if taking phenazopyridine (AZO) at the time of urodynamic study testing will decrease pain experienced by patients after undergoing urodynamic testing.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
04/10/2025
Locations: University of South Florida South Tampa Center, Tampa, Florida
Conditions: Pain After Urodynamic Testing
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Recruiting
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: AdventHealth Medical Group Oncology & Hematology at Orlando, Orlando, Florida
Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Together After Cancer
Recruiting
To evaluate the impact of an adapted online, self-help relationship intervention (supplemented with brief coach calls) for survivors of breast cancer and their partners. Couples will be randomized to receive either the online intervention (Together after Cancer) or usual care (UC) and assessed at baseline, end of the program, and 3 months after randomization.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/10/2025
Locations: Sylvester Comprehensive Cancer Center and University of Miami, Miami, Florida
Conditions: Breast Cancer, Quality of Life, Communication
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Recruiting
This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment. United States Sub-Study: The purpose of this study is to evaluate the safety of mavacamt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Uf Health Jacksonville, Jacksonville, Florida
Conditions: Obstructive Hypertrophic Cardiomyopathy
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Recruiting
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: University of Miami, Miami, Florida
Conditions: Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer